ストックスクリーナーアプリを入手
0.31
6.06%
-0.02
アフターアワーズ：
.32
0.01
+3.23%
Carisma Therapeutics Inc (CARM) 最新ニュース
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World
Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India
Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World
Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow
Carisma Therapeutics Appoints Interim VP of Finance - TipRanks
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN
Carisma downgraded by H.C. Wainwright to neutral - MSN
Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN
Carisma shares downgraded to neutral after program halt - Investing.com
Carisma Therapeutics (NASDAQ:CARM) Cut to Neutral at Robert W. Baird - Defense World
Carisma downgraded by Baird over lack of near-term catalysts - MSN
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Kilgore News Herald
Baird Downgrades Carisma Therapeutics (CARM) - MSN
BTIG cuts Carisma Therapeutics to Neutral from Buy By Investing.com - Investing.com Nigeria
Carisma downgraded by Baird over lack of near-term catalysts (CARM:NASDAQ) - Seeking Alpha
Carisma Therapeutics downgraded to Neutral from Outperform at Baird - MSN
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):